Abstract
Human T-cell lymphotropic virus type 1 (HTLV-1) is a retrovirus which is endemic to certain regions of the world and infects around 10-20 million people. HTLV-1 is the etiologic agent of Adult T cell leukemia/lymphoma and HTLV-1 associated neurological disorders including mainly HTLV-1 associated myelopathy/Tropical spastic paraparesis. The involvement of the central nervous diseases occurs among: HTLV-1 infected patients from endemic areas, HIV positive individuals and drug users. The ability of HTLV-1 to cause associated neuropathies starts with the virus crossing the blood brain barrier (BBB), then entering and infecting the cells of the central nervous system. As a consequence, to the viral attack, HTLV-1 infected lymphocytes produce pro-inflammatory cytokines like tumor necrosis factor alpha, Interleukin 1 beta and interleukin 6 which further disrupts the BBB. Different serological tests have been used in the diagnosis of HTLV-1. These include: ELISA, Western Blotting (WB), Immunofluorescence, Particle Agglutination and Polymerase Chain Reaction which is used as a confirmatory test. Danazol, pentoxifylline, azathioprine and vitamin C have been used in the treatment of the HTLV-1 associated neurological disorders. Other antiviral drugs (lamivudine, zidovudine), monoclonal antibodies (Daclizumab) and therapeutic agents (valporic acid, interferons) have also been evaluated. No known drug, so far, has been shown to be efficacious. The aim of this review is to present the complexities of HTLV-1 associated neurological disorders and their current ongoing treatment. In addition to discussing future possible therapeutic strategies, by targeting HTVL-1 viral components and gene/s products, for the treatment of those neurological conditions.
Keywords: HTLV-1, Reteroviradae, Antiviral drugs, Neurological disorders, Blood brain barrier, Pathogenesis, New drugs discovery.
Current Topics in Medicinal Chemistry
Title:HTLV-1 Associated Neurological Disorders
Volume: 17 Issue: 12
Author(s): Muhammad Yasir Khan, Ishaq Nasib Khan, Muhammad Farman, Saleh Al Karim, Ishtiaq Qadri, Muhammad Amjad Kamal, Khalid Al Ghamdi and Steve Harakeh
Affiliation:
Keywords: HTLV-1, Reteroviradae, Antiviral drugs, Neurological disorders, Blood brain barrier, Pathogenesis, New drugs discovery.
Abstract: Human T-cell lymphotropic virus type 1 (HTLV-1) is a retrovirus which is endemic to certain regions of the world and infects around 10-20 million people. HTLV-1 is the etiologic agent of Adult T cell leukemia/lymphoma and HTLV-1 associated neurological disorders including mainly HTLV-1 associated myelopathy/Tropical spastic paraparesis. The involvement of the central nervous diseases occurs among: HTLV-1 infected patients from endemic areas, HIV positive individuals and drug users. The ability of HTLV-1 to cause associated neuropathies starts with the virus crossing the blood brain barrier (BBB), then entering and infecting the cells of the central nervous system. As a consequence, to the viral attack, HTLV-1 infected lymphocytes produce pro-inflammatory cytokines like tumor necrosis factor alpha, Interleukin 1 beta and interleukin 6 which further disrupts the BBB. Different serological tests have been used in the diagnosis of HTLV-1. These include: ELISA, Western Blotting (WB), Immunofluorescence, Particle Agglutination and Polymerase Chain Reaction which is used as a confirmatory test. Danazol, pentoxifylline, azathioprine and vitamin C have been used in the treatment of the HTLV-1 associated neurological disorders. Other antiviral drugs (lamivudine, zidovudine), monoclonal antibodies (Daclizumab) and therapeutic agents (valporic acid, interferons) have also been evaluated. No known drug, so far, has been shown to be efficacious. The aim of this review is to present the complexities of HTLV-1 associated neurological disorders and their current ongoing treatment. In addition to discussing future possible therapeutic strategies, by targeting HTVL-1 viral components and gene/s products, for the treatment of those neurological conditions.
Export Options
About this article
Cite this article as:
Khan Yasir Muhammad, Khan Nasib Ishaq, Farman Muhammad, Karim Al Saleh, Qadri Ishtiaq, Kamal Amjad Muhammad, Ghamdi Al Khalid and Harakeh Steve, HTLV-1 Associated Neurological Disorders, Current Topics in Medicinal Chemistry 2017; 17 (12) . https://dx.doi.org/10.2174/1568026616666161222141318
DOI https://dx.doi.org/10.2174/1568026616666161222141318 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Challenges, Consequences and Possible Treatments of Anticancer Drug Discovery ll
The use of several compounds has been the subject of increasing interest in phytochemistry, biochemistry, and other fields of research at the chemistry-biology-ecosystems interface. In spite of the continued search for new anticancer drugs, cancer remains a leading cause of death. Cancer mortalities are expected to increase to 12.9 million, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Measles Virus as An Oncolytic Vector Platform
Current Gene Therapy Advances in Clinical Study of Curcumin
Current Pharmaceutical Design Fragment-Based Discovery of Inhibitors of Protein Kinase B
Current Topics in Medicinal Chemistry Aptamers Overview: Selection, Features and Applications
Current Topics in Medicinal Chemistry A Rare Cause of Upper Gastrointestinal Bleeding in Children: Gastric Schwannoma
Current Pediatric Reviews Disrupting the mTOR Signaling Network as a Potential Strategy for the Enhancement of Cancer Radiotherapy
Current Cancer Drug Targets Role of Neural Stem Cells in Parkinsons Disease
Current Signal Transduction Therapy The Role of Intestinal Microbiota in Graft versus Host Disease
Mini-Reviews in Medicinal Chemistry To Die or Not to Die: That is the Autophagic Question
Current Molecular Medicine Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors
Current Medicinal Chemistry Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety RNAi Screening for the Discovery of Novel Modulators of Human Disease
Current Pharmaceutical Biotechnology Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry Development of a STAT5 Phosphorylation Assay as a Rapid Bioassay to Assess Interleukin-7 Potency
Current Pharmaceutical Biotechnology Recent Advances in Anticancer Chemotherapeutics based upon Azepine Scaffold
Anti-Cancer Agents in Medicinal Chemistry Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets Multifunctional Radiolabeled Nanoparticles for Targeted Therapy
Current Medicinal Chemistry Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
Current Topics in Medicinal Chemistry Mechanistic Insights into the Antileukemic Activity of Hyperforin
Current Cancer Drug Targets CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia
Cardiovascular & Hematological Disorders-Drug Targets